ATE302012T1 - Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten - Google Patents
Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamentenInfo
- Publication number
- ATE302012T1 ATE302012T1 AT99928498T AT99928498T ATE302012T1 AT E302012 T1 ATE302012 T1 AT E302012T1 AT 99928498 T AT99928498 T AT 99928498T AT 99928498 T AT99928498 T AT 99928498T AT E302012 T1 ATE302012 T1 AT E302012T1
- Authority
- AT
- Austria
- Prior art keywords
- antilplatets
- prevention
- combined administration
- antihypertensive drugs
- adp receptor
- Prior art date
Links
- 239000002220 antihypertensive agent Substances 0.000 title abstract 2
- 206010008118 cerebral infarction Diseases 0.000 title abstract 2
- 229940127088 antihypertensive drug Drugs 0.000 title 1
- 201000008247 brain infarction Diseases 0.000 title 1
- 230000002265 prevention Effects 0.000 title 1
- 239000005541 ACE inhibitor Substances 0.000 abstract 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 abstract 2
- BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 abstract 1
- 102000015427 Angiotensins Human genes 0.000 abstract 1
- 108010064733 Angiotensins Proteins 0.000 abstract 1
- 239000005552 B01AC04 - Clopidogrel Substances 0.000 abstract 1
- 239000002947 C09CA04 - Irbesartan Substances 0.000 abstract 1
- 102000007466 Purinergic P2 Receptors Human genes 0.000 abstract 1
- 108010085249 Purinergic P2 Receptors Proteins 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 229940127218 antiplatelet drug Drugs 0.000 abstract 1
- 230000000903 blocking effect Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical compound C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 abstract 1
- 229960003009 clopidogrel Drugs 0.000 abstract 1
- 229960002490 fosinopril Drugs 0.000 abstract 1
- YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 abstract 1
- 229960002198 irbesartan Drugs 0.000 abstract 1
- LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical compound C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 abstract 1
- 229950000973 omapatrilat Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Vascular Medicine (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Plant Substances (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8965098P | 1998-06-17 | 1998-06-17 | |
| PCT/US1999/012934 WO1999065500A1 (en) | 1998-06-17 | 1999-06-09 | Preventing cerebral infarction through administration of adp-receptor antiplatelet and antihypertensive drugs in combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE302012T1 true ATE302012T1 (de) | 2005-09-15 |
Family
ID=22218835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99928498T ATE302012T1 (de) | 1998-06-17 | 1999-06-09 | Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6248729B1 (de) |
| EP (1) | EP1087775B1 (de) |
| JP (2) | JP4588877B2 (de) |
| AT (1) | ATE302012T1 (de) |
| AU (1) | AU750122C (de) |
| CA (1) | CA2332608C (de) |
| DE (1) | DE69926750T2 (de) |
| ES (1) | ES2246575T3 (de) |
| PT (1) | PT1087775E (de) |
| WO (1) | WO1999065500A1 (de) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2783422A1 (fr) * | 1998-09-21 | 2000-03-24 | Sanofi Sa | Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire |
| KR20020002487A (ko) * | 1999-03-29 | 2002-01-09 | 스티븐 비. 데이비스 | 협심증 치료를 위한 바소펩티다제 억제제의 용도 |
| WO2001005428A1 (en) * | 1999-07-21 | 2001-01-25 | Takeda Chemical Industries, Ltd. | Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| CA2420055C (en) * | 2000-08-25 | 2010-06-01 | Takeda Chemical Industries, Ltd. | Fibrinogen-lowering agent |
| JP2002138054A (ja) * | 2000-08-25 | 2002-05-14 | Takeda Chem Ind Ltd | フィブリノーゲン低下剤 |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| NZ526540A (en) * | 2000-12-25 | 2004-11-26 | Sankyo Co | Medicinal compositions containing aspirin and 2-acetoxy-5-(alpha-cyclopropylcarbonyl-2-flurobenzyl-4,5,6,7-tetrahydrothieno[3,2-c]pyridine useful in preventing thrombus or embolus diseases |
| US6890918B2 (en) | 2001-04-30 | 2005-05-10 | Shire Laboratories, Inc. | Pharmaceutical compositions including ACE/NEP inhibitors and bioavailability enhancers |
| US20040219208A1 (en) * | 2001-08-03 | 2004-11-04 | Ryu Kawamura | Sustained-release medicines |
| US6669955B2 (en) * | 2001-08-28 | 2003-12-30 | Longwood Pharmaceutical Research, Inc. | Combination dosage form containing individual dosage units of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
| JP2005508358A (ja) * | 2001-10-25 | 2005-03-31 | デポメド・インコーポレイテッド | 胃滞留型ロサルタン投与量を用いる治療方法 |
| CA2467095A1 (en) * | 2001-11-23 | 2003-05-30 | Solvay Pharmaceuticals Gmbh | Hypertonia treatment during the acute phase of a cerebrovascular accident |
| WO2003070278A1 (en) * | 2002-02-19 | 2003-08-28 | Boehringer Ingelheim International Gmbh | Pharmaceutical combination of angiotensin ii antagonists and angiotensin i converting enzyme inhibitors |
| WO2003090723A1 (en) * | 2002-04-23 | 2003-11-06 | Bristol-Myers Squibb Company | Modified-release vasopeptidase inhibitor formulation, combinations and method |
| US8980870B2 (en) * | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
| DE10335027A1 (de) * | 2003-07-31 | 2005-02-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verwendung von Angiotensin II Rezeptor Antagonisten |
| US20050054731A1 (en) * | 2003-09-08 | 2005-03-10 | Franco Folli | Multi-system therapy for diabetes, the metabolic syndrome and obesity |
| ES2282062T1 (es) | 2004-06-04 | 2007-10-16 | Teva Pharmaceutical Industries Ltd. | Composicion farmaceutica que contiene irbesartan. |
| CN101031565B (zh) * | 2004-09-29 | 2010-09-29 | 博尔托拉制药公司 | 取代的2h-1,3-苯并噁嗪-4(3h)-酮 |
| CN103083318A (zh) * | 2004-11-05 | 2013-05-08 | 贝林格尔.英格海姆国际有限公司 | 包含替米沙坦和氨氯地平的双层片剂 |
| US20060201958A1 (en) * | 2005-02-27 | 2006-09-14 | Tieben Anthony M | Mask container |
| CA2614664A1 (en) * | 2005-07-14 | 2007-01-25 | Franco Folli | Daily dosage regimen for treating diabetes, obesity,metabolic syndrome and polycystic ovary syndrome |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| US20080118572A1 (en) * | 2006-10-10 | 2008-05-22 | Harold Richard Hellstrom | Methods and compositions for reducing the risk of adverse cardiovascular events associated with the administration of artificial blood |
| CN101686681B (zh) | 2007-04-27 | 2015-04-01 | 锡德克斯药物公司 | 包含氯吡格雷和磺基烷基醚环糊精的制剂和其使用方法 |
| EP3067043B1 (de) * | 2007-11-06 | 2022-11-30 | Novartis AG | Pharmazeutische zusammensetzungen auf basis von superstrukturen aus einem angiotensinrezeptorantagonisten/-blocker (arb) und einem neutralendopeptidasehemmer (nep) |
| WO2010132711A1 (en) | 2009-05-13 | 2010-11-18 | Cydex Pharmaceuticals, Inc. | Pharmaceutical compositions comprising prasugrel and cyclodextrin derivatives and methods of making and using the same |
| WO2018002673A1 (en) | 2016-07-01 | 2018-01-04 | N4 Pharma Uk Limited | Novel formulations of angiotensin ii receptor antagonists |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2038178B (en) * | 1978-12-29 | 1983-03-09 | Parcor | Antithrombotic therapeutic compsition |
| US4591592A (en) | 1980-07-29 | 1986-05-27 | Syntex (U.S.A.) Inc. | Acid stabilized compositions of thieno-pyridine derived compounds |
| FR2530247B1 (fr) | 1982-07-13 | 1986-05-16 | Sanofi Sa | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique |
| US4558037A (en) * | 1984-06-04 | 1985-12-10 | Merck & Co., Inc. | Cardiovascular composition |
| FR2623810B2 (fr) | 1987-02-17 | 1992-01-24 | Sanofi Sa | Sels de l'alpha-(tetrahydro-4,5,6,7 thieno(3,2-c) pyridyl-5) (chloro-2 phenyl) -acetate de methyle dextrogyre et compositions pharmaceutiques en contenant |
| US5270317A (en) | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| CA2053340C (en) | 1990-10-18 | 2002-04-02 | Timothy P. Burkholder | Mercaptoacetylamide derivatives useful as inhibitors of enkephalinase and ace |
| FR2672801B1 (fr) | 1991-02-14 | 1995-03-03 | Sanofi Sa | Utilisation de derives de tetrahydrothienopyridine comme inhibiteurs de l'angiogenese. |
| AU657793B2 (en) | 1991-09-27 | 1995-03-23 | Merrell Pharmaceuticals Inc. | Novel 2-substituted indane-2-carboxyalkyl derivatives useful as inhibitors of enkephalinase and ACE |
| CA2078759C (en) | 1991-09-27 | 2003-09-16 | Alan M. Warshawsky | Novel carboxyalkyl derivatives useful as inhibitors of enkephalinase and ace |
| EP0534363B1 (de) | 1991-09-27 | 1997-07-09 | Merrell Pharmaceuticals Inc. | 2-Substituierte Indan-2-Mercaptoacetylamid-Verbindungen mit Enkephalinase und ACE-Hemmwirkung |
| JP2712144B2 (ja) * | 1992-02-06 | 1998-02-10 | 田辺製薬株式会社 | 血小板凝集抑制組成物 |
| DE69317764T2 (de) | 1992-02-14 | 1998-07-30 | Merrell Pharmaceuticals Inc., Cincinnati, Ohio | Aminoacetylmercaptoacetylamid derivate mit enkephalinase- und ace-hemmwirkung |
| WO1993023403A1 (en) | 1992-05-15 | 1993-11-25 | Merrell Dow Pharmaceuticals Inc. | NOVEL MERCAPTOACETYLAMIDO PYRIDAZO[1,2]PYRIDAZINE, PYRAZOLO[1,2]PYRIDAZINE, PYRIDAZO[1,2-a][1,2]DIAZEPINE AND PYRAZOLO[1,2-a][1,2]DIAZEPINE DERIVATIVES USEFUL AS INHIBITORS OF ENKEPHALINASE AND ACE |
| RU2124503C1 (ru) | 1992-05-18 | 1999-01-10 | И.Р.Сквибб энд Санз, Инк. | Гетероциклические азотсодержащие производные карбоновой кислоты, способ их получения и фармацевтическая композиция |
| US5504080A (en) | 1992-10-28 | 1996-04-02 | Bristol-Myers Squibb Co. | Benzo-fused lactams |
| AU673857B2 (en) | 1992-10-30 | 1996-11-28 | Aventisub Ii Inc. | Mercaptoacetylamide bicyclic lactam derivatives |
| FI942400L (fi) | 1993-05-25 | 1994-11-26 | Daiichi Seiyaku Co | Lääkeaine hermosairauksia vastaan |
| US5508272A (en) | 1993-06-15 | 1996-04-16 | Bristol-Myers Squibb Company | Compounds containing a fused bicycle ring and processes therefor |
| US5362727A (en) | 1993-07-26 | 1994-11-08 | Bristol-Myers Squibb | Substituted azepino[2,1-a]isoquinoline compounds |
| US5525723A (en) | 1993-11-18 | 1996-06-11 | Bristol-Myers Squibb Co. | Compounds containing a fused multiple ring lactam |
| US5576328A (en) | 1994-01-31 | 1996-11-19 | Elf Sanofi | Method for the secondary prevention of ischemic events |
| FR2744918B1 (fr) | 1996-02-19 | 1998-05-07 | Sanofi Sa | Nouvelles associations de principes actifs contenant un derive de thieno(3,2-c)pyridine et un antithrombotique |
| WO1998011896A1 (en) | 1996-09-18 | 1998-03-26 | Merck & Co., Inc. | Combination therapy for reducing the risks associated with cardiovascular disease |
| FR2783422A1 (fr) | 1998-09-21 | 2000-03-24 | Sanofi Sa | Composition pharmaceutique contenant un antagoniste des recepteurs at1 de l'angiotensine ii et un antiagregant plaquettaire |
-
1999
- 1999-06-09 CA CA2332608A patent/CA2332608C/en not_active Expired - Lifetime
- 1999-06-09 JP JP2000554379A patent/JP4588877B2/ja not_active Expired - Lifetime
- 1999-06-09 ES ES99928498T patent/ES2246575T3/es not_active Expired - Lifetime
- 1999-06-09 US US09/328,812 patent/US6248729B1/en not_active Expired - Lifetime
- 1999-06-09 EP EP99928498A patent/EP1087775B1/de not_active Expired - Lifetime
- 1999-06-09 WO PCT/US1999/012934 patent/WO1999065500A1/en not_active Ceased
- 1999-06-09 AT AT99928498T patent/ATE302012T1/de active
- 1999-06-09 AU AU45551/99A patent/AU750122C/en not_active Expired
- 1999-06-09 PT PT99928498T patent/PT1087775E/pt unknown
- 1999-06-09 DE DE69926750T patent/DE69926750T2/de not_active Expired - Lifetime
-
2010
- 2010-04-22 JP JP2010098640A patent/JP2010159300A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DE69926750D1 (de) | 2005-09-22 |
| AU750122B2 (en) | 2002-07-11 |
| JP2010159300A (ja) | 2010-07-22 |
| DE69926750T2 (de) | 2006-06-29 |
| CA2332608A1 (en) | 1999-12-23 |
| US6248729B1 (en) | 2001-06-19 |
| AU750122C (en) | 2003-02-27 |
| AU4555199A (en) | 2000-01-05 |
| ES2246575T3 (es) | 2006-02-16 |
| EP1087775B1 (de) | 2005-08-17 |
| PT1087775E (pt) | 2005-11-30 |
| WO1999065500A1 (en) | 1999-12-23 |
| CA2332608C (en) | 2010-03-23 |
| JP4588877B2 (ja) | 2010-12-01 |
| EP1087775A4 (de) | 2003-01-02 |
| EP1087775A1 (de) | 2001-04-04 |
| JP2002518335A (ja) | 2002-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE302012T1 (de) | Vorbeugung des hirninfarkts durch kombinierte verabreichung von adp-rezeptor antiblutplättchen und antihypertensiven medikamenten | |
| EE200200086A (et) | Reniin-angiotensiini süsteemi inhibiitori kasutamine, kombineeritud produkt ja meetod kardiovaskulaarsete haigusjuhtude ärahoidmiseks | |
| EP1510221A4 (de) | Mittel zur prävention und/oder behandlung für personen mit expression oder aktivierung von her2 und/oder egfr | |
| BRPI0412557A (pt) | forma de dosagem farmacêutica de eventos cardiovasculares | |
| DK0742711T3 (da) | Tabletter, som er beskyttet mod misbrug | |
| EP1539234A4 (de) | Verfahren zur prävention oder behandlung von zellmalignität durch verabreichung von cd2-antagonisten | |
| EP1708686A4 (de) | Allgemein lineare brauseform von fentanyl zur oralen anwendung und verfahren zur verabreichung | |
| NO20013855L (no) | Fast tilstandsform av celecoxib med ökt biotilgjengelighet | |
| BR0109966A (pt) | Combinação de compostos orgânicos | |
| BR0307508A (pt) | Composto, composição farmacêutica, e, métodos de tratamento ou prevenção de dor e inflamação e de tratamento de doença | |
| PT828728E (pt) | Di-hidrobenzofuranos de fenilo | |
| Konishi et al. | Carbamazepine-induced skin rash in children with epilepsy | |
| DK0828727T3 (da) | Cyclohexyldihydrobenzofuraner | |
| Muriel-Villoria et al. | Comparison of the onset and duration of the analgesic effect of dipyrone, 1 or 2 g, by the intramuscular or intravenous route, in acute renal colic | |
| BR0311903A (pt) | Tratamento para depressão e ansiedade pela combinação de um inibidor de pde iv e um agente antidepressivo ou ansiolìtico | |
| Vinson et al. | Slow infusion for the prevention of akathisia induced by prochlorperazine: a randomized controlled trial | |
| WO1994028924A1 (en) | Combination of angiotensin converting enzyme inhibitors and aii antagonists | |
| DE602004016963D1 (en) | Therapeutisches system mit amoxicillin und clavulansäure | |
| ATE326451T1 (de) | Chinazolin derivate und therapeutische verwendungen davon | |
| KR960706341A (ko) | 유기 인 콜린스테라아제 억제제에 의해 야기되는 중독의 예방 및 예비 치료를 위한 약제 제형(pharmaceutical formulation for preventing or pre-treating poisoning by organophosphoric cholinesterase inhibitors) | |
| ID29818A (id) | Penggunaan antagonis reseptor angiotensin ii untuk mengobati infarksi miokardial | |
| ATE505464T1 (de) | Feste form von amg 706 und pharmazeutische zusammensetzungen davon | |
| DK694188A (da) | Anvendelse af ace-inhibitor til laegemiddelfremstilling, evt. i kombination med et calciumkanalblokeringsmiddel | |
| BG108144A (en) | New use | |
| MX2010004361A (es) | Metodos para inhibir infeccion viral. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1087775 Country of ref document: EP |